We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    neurocognitive communicator | ALS
Previous Study | Return to List | Next Study

NeuroCognitive Communicator: Safety Study (NCC-1701)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03100110
Recruitment Status : Not yet recruiting
First Posted : April 4, 2017
Last Update Posted : April 4, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Individuals suffering from tetraplegia as a result of cervical spinal cord injury, brainstem stroke, or amyotrophic lateral sclerosis (ALS) cannot independently perform tasks of daily living. In many cases, these conditions do not have effective therapies and the only intervention is the provision of assistive devices to increase independence and quality of life. However, currently available devices suffer from usability issues and are limiting for both the patient and caregiver. One of the most progressive alternative strategies for assistive devices is the use of brain-computer interface (BCI) technology to translate intention signals directly from sensors in the brain into computer or device action. Preclinical primate research and recent human clinical pilot studies have demonstrated success in restoring function to disabled individuals using sensors implanted directly in motor regions of the brain. Other preclinical primate research has demonstrated effective intention translation from sensors implemented in cognitive regions of the brain and that this information complements information from the motor regions. The current proposal seeks to build on these studies and to test the safety aspects related to implanting two sensors, each a microelectrode array, into both the motor and cognitive regions of the brain in motor impaired humans. Secondary objectives include feasibility evaluation of the complementary sensors in their ability to support effective assistive communication.

Condition or disease Intervention/treatment
Motor Neuron Disease, Amyotrophic Lateral Sclerosis Tetraplegia Device: NeuroCognitive Communicator

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Official Title: NeuroCognitive Communicator Exploratory Safety Study of an Assistive Neuroprosthetic Device for Patients With Severe Upper Motor Disability.
Anticipated Study Start Date : April 2017
Estimated Primary Completion Date : February 2019
Estimated Study Completion Date : May 2020


Arms and Interventions

Arm Intervention/treatment
Experimental: NeuroCognitive Communicator Device: NeuroCognitive Communicator
Comprises an electrode array in prefrontal cortex, another in motor cortex, Blackrock NeuroPort system and connectors, augmentative assistive communication application, robotic arm, and virtual reality environment.
Other Names:
  • Utah Array
  • Blackrock Microsystems NeuroPort
  • Brain-Computer Interface
  • Brain-Machine Interface


Outcome Measures

Primary Outcome Measures :
  1. Rate of adverse events [ Time Frame: 6 months ]

    Transcutaneous connector will be assessed by physician 3-4 times per week for skull and scalp health and lack of infection.

    All adverse events associated with the system will be measured.


  2. Change in quality of life as assessed by McGill Quality of Life questionnaire. [ Time Frame: 6 months ]
    McGill Quality of Life questionnaire will be administered monthly; shortened version will be administered 3-4 times per week.


Secondary Outcome Measures :
  1. Percentage of allotted time spent with each augmentative and assistive communication technology. [ Time Frame: 6 months ]
    At the end of most experimental sessions, the participant will have time to operate the NCC to control augmentative and assistive communication (AAC) technologies such as robotic arms or spellers. We will measure the percentage of allotted time that the participant spends operating each AAC technology, or choosing not to operate any AAC technology. The data will be aggregated across all AAC sessions with time allotted to AAC operation.

  2. Information transfer rate (measured in bits per second) achieved by each participant calculated during closed-loop operation of the neuroprosthetic device, aggregated across trials within a task. [ Time Frame: 6 months ]
    Participants will perform repeated trials of experimental tasks designed to activate recorded brain regions. Task progression will be modulated by neuronal activity. Successful completion of the task will require volitional modulation of neuronal activity. Task performance will be quantified by the information transfer rate which is calculated from the number of bits of information communicated by each trial's selection(s) and the amount of time it took to complete a trial.

  3. Coefficients of neuronal activity covariance matrix and their dependence on task performance. [ Time Frame: 6 months ]
    Neuronal activity time series covary across neurons within a brain region and across brain regions. The degree of covariance will be recorded in the coefficients of the covariance matrix, scaled from -1 to +1. The covariance matrix will be recorded under different task conditions.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented diagnosis of a complete or incomplete cervical spinal cord injury, with stable neurological deficits greater than 1 year, or ALS with equivalent degree of deficit.
  • Maintain some level of communication, enough to independently provide informed consent for the study.
  • Deemed healthy for surgery.
  • Good psychological and social stability.
  • Prospective participants with ALS must already have an advanced directive with regard to ventilation.
  • Live within a one-hour travel duration of the site.

Exclusion Criteria:

  • Presence of previous certain implanted devices.
  • In the opinion of the investigator, the presence of other serious disease or disorder that could affect ability to participate in this study.
  • Ongoing participation in another clinical trial.
  • Individuals who are immunosuppressed or who have conditions that typically result in immunocompromise (eg. chronic corticosteroid use, immunomodulators, chemotherapy).
  • Presence of clinical depression that is not medically optimized, as screened by a neuropsychologist on our team.
  • Presence of cognitive deficits, as assessed by a neuropsychologist on our team, that would preclude completion of some cognitively challenging tasks.
  • The participant has plans to move outside the study radius within the study period.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03100110


Contacts
Contact: Nella Bianconi 613-737-8899 ext 15073 nbianconi@ohri.ca
Contact: Chadwick Boulay, PhD 613-798-5555 ext 19241 chboulay@ohri.ca

Sponsors and Collaborators
Ottawa Hospital Research Institute
More Information

Responsible Party: Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier: NCT03100110     History of Changes
Other Study ID Numbers: 20170100-01H
First Posted: April 4, 2017    Key Record Dates
Last Update Posted: April 4, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Ottawa Hospital Research Institute:
Brain-Computer Interface
Brain-Machine Interface
Prefrontal Cortex

Additional relevant MeSH terms:
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Quadriplegia
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases
Paralysis
Neurologic Manifestations
Signs and Symptoms